5.72p+0.06 (+0.99%)05 Jul 2022, 11:29
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Immupharma PLC Fundamentals

Company NameImmupharma PLCLast Updated2022-07-05
IndustryBiotechnologySectorHealthcare
Shares in Issue284.985 mMarket Cap£16.29 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.03EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0001Debt Equity Ratio0
Asset Equity Ratio1.3590Cash Equity Ratio0.3624
Quick Ratio1.2451Current Ratio2.11
Price To Book Value3.6550ROCE0

Immupharma PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Immupharma PLC Company Financials

Assets202120202019
Tangible Assets£352,996.00£411,606.00£206,744.00
Intangible Assets£477,553.00£484,042.00£478,959.00
Investments£1.42 m£2.42 m£690,910.00
Total Fixed Assets£2.65 m£3.49 m£2.22 m
Stocks000
Debtors£373,253.00£95,339.00£102,924.00
Cash & Equivalents£1.60 m£5.86 m£1.36 m
Other Assets£405,489.00£174,488.00£843,148.00
Total Assets£6.00 m£10.92 m£5.80 m
Liabilities202120202019
Creditors within 1 year£1.58 m£1.26 m£531,867.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£1.58 m£1.26 m£531,867.00
Net assets£4.41 m£9.65 m£5.27 m
Equity202120202019
Called up share capital£28.50 m£25.02 m£16.74 m
Share Premium£27.24 m£27.24 m£27.19 m
Profit / Loss-£8.94 m-£7.25 m-£6.74 m
Other Equity£4.41 m£9.65 m£5.27 m
Preference & Minorities000
Total Capital Employed£4.41 m£9.65 m£5.27 m
Ratios202120202019
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.35901.35901.3590
Cash / Equity0.36240.36240.3624
EPS-£0.02-£0.03-£0.04
Cash Flow202120202019
Cash from operating activities-£4.83 m-£3.33 m-£4.22 m
Cashflow before financing-£4.13 m£5.04 m-£3.90 m
Increase in Cash-£4.18 m£4.47 m-£4.00 m
Income202120202019
Turnover£118,350.00£126,667.00£77,925.00
Cost of sales000
Gross Profit000
Operating Profit-£6.59 m-£5.59 m-£6.28 m
Pre-Tax profit-£8.94 m-£7.25 m-£6.74 m

Immupharma PLC Company Background

SectorHealthcare
ActivitiesImmuPharma PLC is a drug discovery and development company. Its pipeline includes novel peptide-based therapeutics within four therapy areas: Autoimmunity & Inflammation, Anti-Infectives, Metabolism, and Cancer. Its lead drug candidate is Lupuzor, which is a treatment for lupus and life-threatening autoimmune disease.
Latest Interim Date29 Sep 2021
Latest Fiscal Year End Date25 May 2022

Immupharma PLC Directors

AppointedNamePosition
2021-07-30Dr. Franco Di MuzioNon-Executive Director
2006-03-31Mr. Douglas Gordon James PatersonNon-Executive Director
2022-06-01Mr. Timothy Paul McCarthyExecutive Director,Chairman and Chief Executive Officer
2021-07-30Mr. Dimitri DimitriouExecutive Director,Chief Executive Officer
2021-05-24Dr. Robert Henri ZimmerExecutive Director,President and Chief Scientific Officer
2016-05-05Mr. Richard Leonard WarrExecutive Director,Chairman
2016-05-05Dr. Ajay AgrawalNon-Executive Director
2011-08-09Mr. Paddy Hugh Walker-Taylor FCA,MCTExecutive Director,Chief Financial Officer
2006-03-31Mr. Anthony Johnson B.Pharm,MScNon-Executive Director
2021-08-24Dr. Sanjeev PandyaNon-Executive Director,Senior Independent Director
2021-07-30Dr. Stephane Robert George MeryNon-Executive Director
2022-06-01Mr. Timothy Gary FranklinExecutive Director,Chief Operating Officer
2022-06-01Ms. Lisa BaderoonNon-Executive Director

Immupharma PLC Contact Details

Company NameImmuPharma PLC
AddressOne Bartholomew Close, London, EC1A 7BL
Telephone+44 2071524080
Websitehttp://www.immupharma.com

Immupharma PLC Advisors

StockbrokerBryan, Garnier & Co Limited
Phone+44 2073322500
Nominated AdviserNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
StockbrokerNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
RegistrarComputershare Investor Services PLC
Phone+44 3707020003
Fax+44 3707036101
AuditorNexia Smith & Williamson
Phone+44 2071314000
Fax+44 2071314001
SolicitorBircham Dyson Bell
Phone+44 2072277000
Fax+44 2072223480
BankRoyal Bank of Scotland PLC
AuditorNexia Smith & Williamson Audit Limited